News | Contrast Media | August 02, 2022

Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage. The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August, 2022.

Bracco Diagnostics has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron® (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage.

Photo credit: Getty Images


August 2, 2022 – A new update has been announced as the radiology world continues to address supply disruptions of contrast media.

Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A. has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage, according to a news release issued by the company July 27, from its headquarters in Milan, Italy.

Iomeron (iomeprol injection) is a nonionic iodinated contrast medium for intravascular use in adults in various imaging procedures. Currently registered in over 50 countries in Europe and Asia, it is not approved for use in the United States.

The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August, 2022. It is manufactured at two Bracco locations: BIPSO GmbH, Singen (Germany), and Patheon Italia S.p.A., Ferentino (Italy).

The company offered detailed information on the temporary importation, including Importation Discretion Documentation and a Letter to Healthcare Professionals.

“We are proud that the company has worked proactively with the FDA to address the shortage of iodinated contrast agents in the U.S. market,” said Jeff Fleming, Chief Executive Officer, Bracco Diagnostics Inc. “Throughout its 95-year history, Bracco has always put people and innovation at the core of its business, and focused ongoing attention on patient health, safety, and quality of care,” added Fleming.

The temporary importation being allowed by the FDA addresses shortages of GE Healthcare’s Omnipaque (iohexol injection) and Visipaque (iodixanol injection), and Bayer’s Ultravist (iopromide injection) which resulted from COVID-19 related supply disruptions. 

Related coverage on the contrast media shortage can be found here:

https://www.itnonline.com/content/global-contrast-media-shortage-strate…

https://www.itnonline.com/content/global-contrast-media-shortage-means-…

Related Content

News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Computed Tomography (CT)

August 4, 2022 — Xoran Technologies announces that last month it received FDA 510(k) clearance for TRON — a truly mobile ...

Time August 04, 2022
arrow
News | Contrast Media

August 3, 2022 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), electronic health ...

Time August 03, 2022
arrow
News | Mobile C-Arms

July 29, 2022 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the ARTIS icono ...

Time July 29, 2022
arrow
News | ECR

July 25, 2022 — Dunlee unveiled its new oncology bundles for the first time this year, launched at the 2022 European ...

Time July 25, 2022
arrow
News | AHRA

July 18, 2022 — 3DR Labs, an Accumen company, today announced the launch of its Cardiac Center of Excellence and Imaging ...

Time July 19, 2022
arrow
News | Contrast Media

July 18, 2022 — Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the ...

Time July 18, 2022
arrow
News | Lung Imaging

July 13, 2022 — KA Imaging, a company that develops innovative X-ray imaging solutions, announced the initial results ...

Time July 13, 2022
arrow
News | Artificial Intelligence

July 12, 2022 — The DeepCT is a leading AI-driven system developed by Deep01 to identify abnormal CT scan images ...

Time July 12, 2022
arrow
News | SCCT

July 8, 2022 — The Society of Cardiovascular Computed Tomography (SCCT) has released a new expert consensus document on ...

Time July 08, 2022
arrow
Subscribe Now